Transcatheter Aortic Valve Implantation: Bahrain Experience

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Transcatheter aortic valve implantation (TAVI) is a minimally invasive alternative to surgical aortic valve replacement (sAVR).
• Assessing TAVI's real-world effectiveness and safety is crucial for patient selection and procedural optimization.

Purpose of the Study:

• To evaluate the baseline characteristics, procedural details, and one-year clinical outcomes of TAVI patients in Bahrain.
• To compare local TAVI outcomes with international benchmarks.

Main Methods:

• Retrospective analysis of a prospectively designed cohort of 81 consecutive TAVI patients.
• Data collected from February 2014 to February 2019 at Mohammed bin Khalifa Cardiac Centre.
• Clinical endpoints assessed using Valve Academic Research Consortium-2 (VARC-2) criteria.

Main Results:

• The study included 81 patients with a mean age of 76.4 years and significant cardiac risk scores.
• One-year all-cause mortality was low at 3.7%, with no cardiovascular deaths.
• TAVI-related complications were infrequent, including TAV-in-TAV deployment (4.9%), major bleeding (1.2%), and vascular complications (2.5%).
• Significant Acute Kidney Injury (AKI) occurred in 2.5% of patients, with no progression to stage-3 or need for dialysis.
• Permanent pacemaker implantation was required in 8.6% of patients.

Conclusions:

• The TAVI program in Bahrain demonstrates encouraging results.
• Procedural success and complication rates align with outcomes reported by leading international centers.
• TAVI is a safe and effective treatment option in the Bahraini population.